Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

IDEXX Laboratories Inc Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance


Tuesday, 29 Jan 2013 07:00am EST 

IDEXX Laboratories Inc announced that for fiscal 2013, it expects revenue to be in the range of $1.405 to $1.42 billion, which represents reported growth of 8.5% to 9.5% relative to 2012. Organic revenue growth is estimated to be in the range of 8% to 9% and is consistent with previous guidance. Earnings per share (EPS) are expected to be $3.47 to $3.57, compared to guidance of $3.37 to $3.47. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $1.405 billion and EPS of $3.48 for fiscal 2013. 

Company Quote

148.24
0.26 +0.18%
19 Dec 2014